Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection
暂无分享,去创建一个
C. Wheeler | M. Lehtinen | S. Garland | D. Ferris | A. Saah | J. Paavonen | E. Joura | D. Radley | M. Steben | H. Sings | R. Haupt | Margaret K. James | K. Giacoletti | Darron R. Brown | M. James | Darron R. Brown | C. Wheeler | Katherine E. D. Giacoletti
[1] C. Wheeler,et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection , 2009, Human vaccines.
[2] B Romanowski,et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.
[3] R. Railkar,et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. , 2009, The Journal of infectious diseases.
[4] M. Lehtinen,et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. , 2008, American journal of epidemiology.
[5] D. Harper. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. , 2008, Gynecologic oncology.
[6] J. Berkhof,et al. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening , 2008, British Journal of Cancer.
[7] A. Chaturvedi,et al. Hematologic and biochemical changes associated with human T lymphotropic virus type 1 infection in Jamaica: a report from the population-based blood donors study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] D. Lowy,et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.
[9] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[10] M. Lehtinen,et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. , 2007, Vaccine.
[11] K. Ault. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.
[12] C. Wheeler,et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials , 2007, The Lancet.
[13] Daron G Ferris,et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.
[14] F. X. Bosch,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .
[15] Edson Duarte Moreira Júnior,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.
[16] L. Shulman. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. , 2007, The Journal of infectious diseases.
[17] C. Wheeler,et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.
[18] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[19] M. Stanley. Immune responses to human papillomavirus. , 2006, Vaccine.
[20] C. Wheeler,et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[21] K. Jansen,et al. Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18 , 2005, Clinical Diagnostic Laboratory Immunology.
[22] David R. Scott,et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.
[23] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[24] J. Fortenberry,et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. , 2005, The Journal of infectious diseases.
[25] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[26] U Menon,et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study , 2003, The Lancet.
[27] M. Henry. The Bethesda System 2001: an update of new terminology for gynecologic cytology. , 2003, Clinics in laboratory medicine.
[28] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[29] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[30] K. Holmes,et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection , 1992, The New England journal of medicine.